Completed PHASE2 INTERVENTIONAL 1-arm NCT00559091

A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia (Borden-001)

A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes

Sponsor: Jewish General Hospital

Interventions ribavirin

Updated 6 times since 2017 Last updated: Dec 20, 2022 Started: Apr 30, 2007 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00559091, this PHASE2 trial focuses on Acute Myelocytic Leukemia and remains completed. Sponsored by Jewish General Hospital, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jewish General Hospital
The Leukemia and Lymphoma Society

Data source: Jewish General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada
• Montreal, Canada